Latest News and Press Releases

Bemærk venligst, at rapporten udelukkende findes på engelsk. ALK reports Q2 revenue up 17%, EBITDA up 123%, and full-year outlook upgraded (unaudited) Performance in Q2 was better than expected...

ALK reports Q2 revenue up 17%, EBITDA up 123%, and full-year outlook upgraded (unaudited) Performance in Q2 was better than expected with double-digit growth in all regions and ALK reported its...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) offentliggør delårsrapport for første halvår 2022 torsdag den 11. august 2022. ALK afholder samme dag kl. 13.30 (CEST) en telefonkonference for investorer...

On Thursday, 11 August 2022, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its six-month interim report (Q2) 2022. ALK will host a meeting for analysts and institutional investors that day at...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddeler i dag, at selskabet baseret på et stærkt salgsmomentum og forventningerne til resten af året har opjusteret forventningerne til hele året. Som følge...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that based on a strong sales momentum and the outlook for the remainder of the year, ALK has upgraded its full-year outlook. As a result: ...

Four leading experts in respiratory allergy spotlight the impact of respiratory allergy in children, in an ALK-sponsored symposium at the EAACI CongressThe growing availability of evidence-based...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK igangsætter et klinisk fase I-studie med sin nye, sublinguale tabletvaccine (SLIT-tablet) til behandling af peanutallergi. Studiet markerer den...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK initiates a Phase I clinical trial of its novel investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy. The...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af...